News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

TriReme Medical Inc. Lines Up Asian Strategy With Key Appointment of New Board Members



5/9/2011 7:18:37 AM

PLEASANTON, Calif., May 9, 2011 /PRNewswire/ -- TriReme Medical, Inc. (TriReme), a leading developer of innovative catheters and stents for the treatment of complex vascular disease, announced today the appointment of Mr. Supratim Bose and Mr. Michael Kleine to their Board of Directors.

Mr. Bose, Founder and CEO of Bose Consulting Group, is based in Singapore and was until recently Company Group Chairman at Johnson & Johnson with responsibilities for all of the Medical Devices & Diagnostics franchises across the Asia-Pacific Region. Mr. Bose was also a member of the Worldwide Group Operating Committee at Johnson & Johnson Medical Devices & Diagnostics Group.

Mr. Kleine was previously President and CEO of Biosensors International (SGX), a medical device company listed on the Singapore Stock Exchange. He brings vast experience in medical devices having held CEO and President positions at Microvention, Thermo Cardiosystems, Sorin Biomedical and Bird Medical.

"TriReme is developing an exciting range of innovative and differentiated devices and I am excited to help lead their Asian centered strategy," commented Mr. Bose. Mr. Kleine added, "TriReme has created a truly global vision and its expansion is supported by a strong pipeline of unique products."

"Supratim and Mike's enormous experience with the Asian markets provide an extended dimension to both our Board and management teams. TriReme is honored to have the endorsement of both industry veterans who support and share our global vision of medtech growth and development in Asia," said Eitan Konstantino, PhD, President and Chief Executive Officer of TriReme.

About TriReme Medical, Inc.

Based in Pleasanton, California, TriReme Medical, Inc. is a privately held medical device company dedicated to the development, manufacturing, and commercialization of next generation percutaneous devices for the treatment of complex coronary and peripheral arterial disease. The Company's novel balloon and stent therapies are specifically designed for large, unmet clinical needs.

SOURCE TriReme Medical, Inc.


Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES